Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum Meeting Abstract


Authors: Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; Kelsen, D.; Umeda, S.; Bandlamudi, C.; Riaz, N.; Berger, M.; Balachandran, V.; Peer, D.; Capanu, M.; Iacobuzio-Donahue, C.; O'Reilly, E. M.
Abstract Title: Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
Meeting Title: ESMO Congress 2024
Journal Title: Annals of Oncology
Volume: 35
Issue: Suppl. 2
Meeting Dates: 2024 Sep 13-17
Meeting Location: Barcelona, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2024-09-01
Start Page: S922
Language: English
ACCESSION: WOS:001326612902126
DOI: 10.1016/j.annonc.2024.08.1567
PROVIDER: wos
Notes: Meeting Abstract: 1504MO -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joanne Fu-Lou Chou
    333 Chou
  2. Nadeem Riaz
    421 Riaz
  3. Anna Mary Varghese
    146 Varghese
  4. Marinela Capanu
    388 Capanu
  5. Kenneth Ho-Ming Yu
    164 Yu
  6. Eileen O'Reilly
    790 O'Reilly
  7. Michael Forman Berger
    768 Berger
  8. David P Kelsen
    538 Kelsen
  9. Dana Pe'er
    110 Pe'er
  10. Wungki Park
    99 Park
  11. Jessica Yang
    10 Yang
  12. Fiyinfolu Oladele Balogun
    15 Balogun
  13. Shigeaki Umeda
    8 Umeda
  14. Mary Helen Larsen
    2 Larsen